Navitoclax, which inhibits BCL-2, BCL-X, and BCL-W, was being tested in combination with bendamustine and rituximab in patients with relapsed DLBCL as part of the NAVIGATE study, but recruitment was terminated due to non-safety-related reasons (NCT01423539). This evidence concerns the gene BCL2L1 and diffuse large B-cell lymphoma.